CP-547632 HCl (PAN90806), a novel isothiazole, is a orally-bioavailable and ATP-competitive inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases with IC50s of 11 nM and 9 nM, respectively.

Dovitinib Lactate (formerly TKI-258 lactate; CHIR-258 lactate), a benzimidazole-quinolinone analog, is a potent, orally bioavailable and multitargeted RTK inhibitor with potential antineoplastic activity.

XL999, a Spectrum Selective Kinase Inhibitor(TM) (SSKIs), is a potent inhibitor of key RTKs implicated in the development and maintenance of tumor vasculature and in the proliferation of some tumor cells.

BMS-794833 (BMS794833; BMS 794833) is an ATP competitive multi-kinase (Met/VEGFR2) inhibitor with potential anticancer activity.

Cabozantinib malate (formerly known as XL-184 or BMS-907351; trade name Cometriq) is the malate salt form of Cabozantinib, a novel, potent and orally bioavailable VEGFR2 inhibitor with potential anticancer activity.

Sunitinib (formerly also known as SU11248; trade name: Sutent) is a potent, orally bioavailable and multi-targeted RTK (receptor tyrosine kinase) inhibitor with potential antitumor activity.

(Z)-Guggulsterone, the cis-isomer of Guggulsterone, is a naturally occuring phytosteroid isolated from the resin of the guggul plant, Commiphora mukul.

UNC0064-12 is useful chemical agent for research use.

Cediranib maleate (AZD-2171; Recenti, an indole ether quinazoline derivative), the maleate salt of Cediranib, is a novle and highly potent VEGFR (KDR) inhibitor with anticancer activity.

BFH772 (also known as BFH-772) is a novel and potent orally bioavailable VEGFR2 inhibitor that targets VEGFR2 kinase with IC50 of 3 nM.